$5 x 700m (heads + option) = $3.5b$30 x 700m = $21 billon (Prr...

$5 x 700m (heads + option) = $3.5b

$30 x 700m = $21 billon

(Prr will have need to issue a few hundred mio shares for the 23Nov09 SPP, and other future SPPs .
Say total issued 1b)

$30 x 1,000m = $30 billion mkt cap
WOW!


Some of the comments here

(by cheerleaders, gatekeepers, traders wanting to sell out)

are believable, provided we all bear in mind even the most promising Phase lll still has a likely chance of a flop.


re
Chelsea Therapeutics is a case in point

By Sung Moss 09/25/09 - 09:45 AM ED

Failing late-stage, trial results for a drug meant to treat a neurological low-blood-pressure disorder eviscerated all of the gains made in the company's share price since May.

--------------------------------------------------

Chelsea Trial Flops; Shares Rise After the Fall

http://www.thestreet.com/story/10603364/chelsea-trial-flops-shares-rise-after-the-fall.html


CHARLOTTE, N.C. (TheStreet)

-- When the closing bell rang at 4 p.m. on Thursday and the selloff came to a merciful end, Chelsea Therapeutics saw two-thirds of its market cap disappear.

Failing late-stage, trial results for a drug meant to treat a neurological low-blood-pressure disorder eviscerated all of the gains made in the company's share price since May.

At the finish on Thursday, Chelsea Therapeutics plunged $4.29, or 61%, to close at $2.73 on whopping volumes that topped some 56.9 million shares.

But the roller coaster ride continued on Friday morning, as shares were clawing back 27 cents, or 10%, at $3.00.

The biopharm concern said in a press release that preliminary results for the first of two phase III trials of the drug Droxidopa, which is intended to treat symptoms for neurogenic orthostatic hypotension, showed that "it did not demonstrate a statistically significant improvement relative to placebo."

NOH is a disorder where a person's blood pressure plummets after standing up. The drug failed to discernibly help symptoms of dizziness or lightheadedness, which was the primary focus of the double-blind trial.

However, Chelsea Therapeutics did note that the drug was well tolerated with no significant adverse effects, while CEO Dr. Simon Pedder cited "encouraging" secondary measures in the statement.

-- Written by Sung Moss in New York